Evaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: The PSA RapidScreen test

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 3, 2005, Pages 219-223

  Miano, R ^a,c   Mele, G O ^b   Germani, S ^a   Bove, P ^a   Sansalone, S ^a   Pugliese, P F ^b   Micali, F ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b Italian Tumour League   (Italy)

^c NONE   (Italy)

Author keywords

Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CAPILLARY BLOOD; CHROMATOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; IMMUNOASSAY; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITATIVE DIAGNOSIS; QUANTITATIVE ASSAY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CHROMATOGRAPHY; FEMALE; HUMANS; IMMUNOASSAY; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 31044448734     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500802     Document Type: Article

References (20)

1. American Cancer Society, Inc. Cancer Facts and Figures 2004. American Cancer Society, Inc: Atlanta, Ga, 2004, pp 1-56.
2. Crawford ED. Prostate cancer awareness week: September 22-28, 1997. CA Cancer J Clin 1997; 47: 288-296.
3. Catalona WJ et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-1290.
4. Stephenson RA, Stanford JL. Population-based prostate cancer trends in the United States: Patterns of change in the era of prostate-specific antigen. World J Urol 1997; 15: 331-335.
5. Merrill RM, Stephenson RA. Trends in mortality rates inpatients with prostate cancer during the era of prostate specific antigen screening. J Urol 2000; 163: 503-510.
6. Bartsch G et al. Prostate cancer mortality after the introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417-424.
7. Meyer F, Moore L, Bairati I, Fradet Y. Downward trend in prostate cancer mortality in Quebec and Canada. J Urol 1999; 161: 1189-1191.
8. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000; 11: 167-170.
9. Optenberg SA, Thompson IM. Economics of screening for carcinoma of the prostate. Urol Clin North Am 1990; 17: 719-737.
10. Littrup PJ et al. Cost-effective prostate cancer detection. Cancer 1994; 74: 3146-3158.
11. Potter SR et al. Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology 2001; 57: 1100-1104.
12. Martin E et al. Final results of a screening campaign for prostate cancer. Eur Urol 1999; 35: 26-31.
13. Gustafsson O et al. Diagnostic methods in the detection of prostate cancer. A study of a randomly selected population of 2,400 men. J Urol 1992; 148: 1827-1831.
14. Reissigl A et al. Prostate carcinoma screening in the county of Tyrol, Austria: Experience and results. Cancer 1997; 80: 1818-1829.
15. Berg W, Linder C, Eschholz G, Schubert J. Pilot study of the practical relevance of a one-step test for prostate-specific antigen in capillary blood to improve the acceptance rate in the early detection program of prostate carcinoma. Int Urol Nephrol 2001; 32: 381-388.
16. Dok An C, Yoshiki T, Lee G, Okada Y. Evaluation of a rapid qualitative prostate specific antigen assay, the One Step PSA™ test. Cancer Lett 2001; 162: 135-139.
17. Jung K et al. Rapid detection of elevated prostate-specific antigen levels in blood: Performance of various membrane strip tests compared. Urology 1999; 53: 155-160.
18. Madersbacher S, Mian C, Maier U, Simak R. Validation of a 10-minute dipstick test for serum prostate-specific antigen. Eur Urol 1996; 30: 446-450.
19. Carvalhal GF et al. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4ng/ml or less. J Urol 1999; 161: 835-839.
20. Roehl KA, Antenor JA, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6-4.0 ng/ml range. J Urol 2002; 168: 922-925.